Clin2
NCT07225816Possibly a fitRecruiting

How fasting affects stomach food with GLP-1 drugs

Obesity

Treatments studied

Part of Hormones & metabolism clinical trials.

This study looks at how long fasting and temporarily stopping certain diabetes or weight-loss medications (like semaglutide or liraglutide) affects how much food stays in your stomach. It may help understand how these medications work in people who are overweight.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
71 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are 18 years or older.
  • Your body mass index (BMI) is between 25 and 45, and your weight is mainly due to extra body fat.
  • You do not have serious stomach or digestive problems (like slow stomach emptying or severe reflux).
  • You have not had major stomach surgery (like gastric bypass) and do not have a stomach implant.
  • You are willing to fast (no eating or drinking) for a while and eat only the meals we provide.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05340868Recruiting
Study body response to oral semaglutide in overweight adults

This study looks at how genetics may affect your body’s early response to oral semaglutide, a weight-related diabetes medicine. You may be considered if you are overweight (or overweight with prediabetes) and can safely take part in the research.

Bialystok, Podlaskie Voivodeship
NCT07729332Not yet recruiting· Phase 4
Switching to oral weight-loss pills to prevent weight regain after stopping GLP-1 injections

This study tests whether switching to an oral weight-loss medication can help you keep off the weight you lost after stopping a GLP-1 injection like semaglutide or tirzepatide. You might qualify if you live in Massachusetts, are between 18 and 80, have a BMI of 30 or higher, lost at least 10% of your body weight on these injections, and are willing to be randomly assigned to a new treatment.

Boston, Massachusetts
NCT05071898Recruiting· Phase 1
Studying how genetics affect response to GLP-1 weight-loss drugs

This early-stage study looks at how genetic factors may change how people respond to a GLP-1 medicine (semaglutide). The goal is to learn who may benefit most and why, so future treatments can be better matched.

Lancaster, Pennsylvania
NCT07770841Recruiting· Phase 3
Oral medication for weight loss study

This study tests an oral medicine (semaglutide) to see if it helps adults with excess weight lose weight. It might offer an easier, pill-based treatment option for weight management.

Birmingham, Alabama
NCT07627074Recruiting
Real-world weight loss study with semaglutide

This study tracks how semaglutide (an injectable medication that reduces appetite) helps adults lose weight in everyday life. Researchers want to understand how well it works and how safe it is for people starting the treatment.

Seattle, Washington
NCT07006142Recruiting
Fasting time and stomach volume for GLP-1 patients

This trial studies how a longer fasting period affects stomach contents in people taking GLP-1 receptor agonists (a type of diabetes or weight-loss drug). It helps doctors understand if extra fasting time is needed before an upper endoscopy (a camera test for the stomach).

Rochester, Minnesota

Hear when a new Obesity trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.